Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANTHERAS: Pembrolizumab and Valemetostat in HNSCC
NCT05879484Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jul 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valemetostat in head and neck squamous cell carcinoma (HNSCC), squamous cell carcinoma of the lung (SCCL), sinonasal carcinoma, sponsored by National Cancer Institute. Planned start Jul 2025; status: withdrawn.
02
Drugs
valemetostat
03
Conditions
head and neck squamous cell carcinoma (HNSCC)squamous cell carcinoma of the lung (SCCL)sinonasal carcinoma
Beyond the preview
Go deeper on NCT05879484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879484.